spacer
home > white papers > Wrap Around Label - A Lot of Content in a Small Space - Faubel & Co. Nachfolger GmbH
WHITE PAPERS
logo_Faubel_&_C3.JPG

Faubel & Co. Nachfolger GmbH

phone +49 5661 7309-0
email info@faubel.de
web http://www.faubel.de
email Schwarzenberger Weg 45, 34212 Melsungen

Wrap Around Label - A Lot of Content in a Small Space

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. The CRO has been purchasing Faubel labels for several years now. This often involves booklet labels for vials and boxes that also require one label with texts in multiple languages. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>


Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16th– 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement